Why the study?
Does oral anticoagulation therapy beyond 3 months after radiofrequency ablation of atrial fibrillation improve clinical outcomes regarding thromboembolism and serious bleeding?
Does oral anticoagulation therapy beyond 3 months after radiofrequency ablation of atrial fibrillation improve clinical outcomes regarding thromboembolism and serious bleeding?
Answers are grounded in this paper and cite their sources.
In a Danish nationwide cohort, the risk of serious bleeding with oral anticoagulation beyond 3 months post-ablation for atrial fibrillation appears to outweigh the benefits of thromboembolic risk reduction.
Thromboembolic risk beyond 3 months after RFA was relatively low compared with a matched non-ablated AF cohort. With cautious interpretation due to low number of events, serious bleeding risk associated with OAC seems to outweigh the benefits of thromboembolic risk reduction. Randomized studies are warranted to test our results.
No takes yet. Share an insight, caveat, or question.
Karasoy et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: